Status:
COMPLETED
Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).
Lead Sponsor:
Pfizer
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
This study is to evaluate available local data in Iraq patients with moderate-to-severe plaque psoriasis on Enbrel treatment with regards to efficacy, treatment for PsO who have difficult to treat sit...
Eligibility Criteria
Inclusion
- Moderate-to-severe plaque psoriasis patients whom have been receiving etanercept for at least 1 year duration.
- Have difficult to treat sites at presentation.
- Age ≥18 years.
- No history of using other biological treatments, other than etanercept for the treatment of moderate-to-severe PsO.
Exclusion
- Etanercept use for treatment of moderate-to-severe PsO less than 1 year duration.
- Previous use of another biological treatment for treatment of moderate-to-severe PsO.
Key Trial Info
Start Date :
July 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2020
Estimated Enrollment :
486 Patients enrolled
Trial Details
Trial ID
NCT04428411
Start Date
July 5 2020
End Date
August 30 2020
Last Update
October 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
Baghdad, Iraq